0001933414-24-000034.txt : 20240712 0001933414-24-000034.hdr.sgml : 20240712 20240712163759 ACCESSION NUMBER: 0001933414-24-000034 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240711 FILED AS OF DATE: 20240712 DATE AS OF CHANGE: 20240712 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Levy Adam Scott CENTRAL INDEX KEY: 0001693134 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41614 FILM NUMBER: 241114956 MAIL ADDRESS: STREET 1: C/O MIRAGEN THERAPEUTICS, INC. STREET 2: 6200 LOOKOUT ROAD, #100 CITY: BOULDER STATE: CO ZIP: 80301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Mineralys Therapeutics, Inc. CENTRAL INDEX KEY: 0001933414 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 150 N. RADNOR CHESTER ROAD STREET 2: SUITE F200 CITY: RADNOR STATE: PA ZIP: 19087 BUSINESS PHONE: (888) 378-6240 MAIL ADDRESS: STREET 1: 150 N. RADNOR CHESTER ROAD STREET 2: SUITE F200 CITY: RADNOR STATE: PA ZIP: 19087 4 1 wk-form4_1720816673.xml FORM 4 X0508 4 2024-07-11 0 0001933414 Mineralys Therapeutics, Inc. MLYS 0001693134 Levy Adam Scott 150 N. RADNOR CHESTER ROAD, SUITE F200 RADNOR PA 19087 0 1 0 0 CFO and Secretary 1 Common Stock 2024-07-11 4 S 0 10757 13.1444 D 247611 D The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2023. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.93 to $13.43. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. This balance includes 2,906 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported. /s/ Adam Levy 2024-07-12